Article

MMRF's CoMMpass Study Highlights and Moves Research of Myeloma Forward

Anne Young Quinn, of the MMRF, explains the catalyst behind the CoMMpass study and how it may be changing the future of myeloma treatment.

The Multiple Myeloma Research Foundation initiated the CoMMpass study in 2011. The study, which is nearing enrollment completion, uses clinical samples from participants enrolled in the study to help unravel genetic secrets that could lead to new and better treatments for myeloma.

Anne Young Quinn, of the MMRF, explains the catalyst behind the CoMMpass study and how it may be changing the future of myeloma treatment.

Related Videos
Dr. Michael Bogenschutz
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker
Related Content
Image of man with grey hair.
January 16th 2025

An Expert Breaks Down the Meaning of MRD Testing in Cancer Care

Ryan Scott
Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of doctor consulting nurse.
January 12th 2025

The Gift of a Second Chance After My Stem Cell Transplant

Aswita Tan-McGrory
After experiencing unexplained symptoms, I was diagnosed with multiple myeloma and underwent a stem cell transplant.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Illustration of bald man.
January 7th 2025

A Year of Resilience: Looking Back After a Myeloma Diagnosis

Ronald Chin
2024 was a year of resilience after a myeloma diagnosis, marked by a return to public speaking, a documentary filming experience and a fundraising walk.
Image of woman with blondish hair.
December 30th 2024

Empowering Patients With Cancer Through Clear Clinical Trial Communication

Darlene Dobkowski, MA
A clinical trial manager emphasizes the importance of a phased approach to educating patients about complex protocols and potential side effects.